Aditxt Provides Business Update and Files Third Quarter 2020 10-Q
November 13 2020 - 8:00AM
via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the
“Company”) (Nasdaq: ADTX), a life sciences company developing
biotechnologies specifically focused on improving the health of the
immune system through immune monitoring and reprogramming, today
provided a business update in conjunction with the filing of its
Form 10-Q with the Securities and Exchange Commission.
Amro Albanna, Co-Founder and CEO of Aditxt,
commented, “It’s been an exciting quarter for Aditxt that started
with our successful IPO and Nasdaq listing in early July, followed
several weeks later by a successful follow-on public offering.
During the quarter we also added well-known industry names to our
team and advisory board. Most importantly, we introduced the first
application of our AditxtScore™ Monitoring platform, AditxtScore™
for COVID-19, for use in detecting antibodies against SARS-CoV-2
antigens, and for which we are awaiting a response from the U.S.
Food and Drug Administration regarding the Emergency Use
Authorization (EUA) application that we filed in August. As we’ve
announced, we’re working hard to position the Company for
commercialization of this product. We believe that Aditxt has
accomplished much during its first quarter as a public company, and
with cash of $13.7 million at September 30th to support the
execution of our strategy, we are well positioned to achieve our
goals for growth.”
For Aditxt’s complete financial results for the
period ended September 30, 2020, see the Company’s quarterly report
on Form 10-Q that was filed with the Securities and Exchange
Commission on November 13, 2020.
About Aditx Therapeutics Aditxt
is developing technologies specifically focused on improving the
health of the immune system through immune monitoring and
reprogramming. The immune monitoring technology is designed to
provide a personalized comprehensive profile of the immune system.
The immune reprogramming technology is currently at the
pre-clinical stage and is designed to retrain the immune system to
induce tolerance with an objective of addressing rejection of
transplanted organs, autoimmune diseases, and allergies. For more
information, please visit: www.aditxt.com.
Forward-Looking Statements Certain statements
in this press release constitute “forward-looking statements”
within the meaning of the federal securities laws. Forward looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things, the Company’s ongoing and planned
product development; the Company’s intellectual property position;
the Company’s ability to develop commercial functions; expectations
regarding product launch and revenue; the Company’s results of
operations, cash needs, spending, financial condition, liquidity,
prospects, growth and strategies; the industry in which the Company
operates; and the trends that may affect the industry or the
Company. Forward-looking statements are not guarantees of future
performance and actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, as well as those risks more fully
discussed in the section entitled “Risk Factors” in the Company’s
prospectus, dated September 1, 2020, that was filed with the
Securities and Exchange Commission under File No. 333-248491, as
well as discussions of potential risks, uncertainties, and other
important factors in the Company’s subsequent filings with the
Securities and Exchange Commission. All such statements speak only
as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether
as a result of new information, future events or otherwise.
Investor Relations: PCG Advisory Jeff Ramson Chief
Executive Officer IR@aditxt.com 646-762-4518 www.aditxt.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024